Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29037985 | 0.81 | KEAP1 (0.40) | KEAP1NFE2L2CES2CES1 | |
| SCHEMBL10812148 | 0.73 | CES2 (0.42) | EPHX1KEAP1NFE2L2CES2CES1 | |
| SCHEMBL6316603 | 0.70 | EPHX1 (0.41) | EPHX1KEAP1NFE2L2CES2CES1 | |
| SCHEMBL8846296 | 0.70 | KEAP1 (0.45) | EPHX1KEAP1NFE2L2CES2CES1 | |
| SCHEMBL7080108 | 0.70 | EPHX1 (0.41) | EPHX1KEAP1NFE2L2CES2CES1 | |
| SCHEMBL2842403 | 0.70 | EPHX1 (0.41) | EPHX1KEAP1NFE2L2CES2CES1 | |
| SCHEMBL20472266 | 0.70 | EPHX1 (0.37) | EPHX1KEAP1NFE2L2CES2CES1 | |
| SCHEMBL29416278 | 0.70 | EPHX1 (0.37) | EPHX1KEAP1NFE2L2CES2CES1 | |
| SCHEMBL29013937 | 0.69 | EPHX1 (0.39) | EPHX1KEAP1NFE2L2CES2CES1 | |
| SCHEMBL2848234 | 0.67 | EPHX1 (0.37) | EPHX1KEAP1NFE2L2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946474-B2 | Nitrogen-containing compounds and their use as glycine transport inhibitors | MERCK & CO., INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040034069-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | disclosed |
| US-20020082283-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | GLIATECH, INC. | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082283-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | SLC1A5, SLC6A7, SLC6A15 | EPHX1 3387/4885KEAP1 1152/4885NFE2L2 1912/4885 |
| US-20040034069-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | SLC1A5, SLC6A7, SLC6A15 | EPHX1 3387/4885KEAP1 1152/4885NFE2L2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.